Myeloid molecular characteristics of human gamma delta T cells support their acquisition of tumor antigen-presenting capacity
Human T cells expressing gamma delta T cell receptor have a potential to show antigen-presenting cell-like phenotype and function upon their activation. However, the mechanisms that underlie the alterations in human gamma delta T cells remain largely unclear. In this study, we have investigated the...
Gespeichert in:
Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2015-08, Vol.64 (8), p.941-949 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Human T cells expressing gamma delta T cell receptor have a potential to show antigen-presenting cell-like phenotype and function upon their activation. However, the mechanisms that underlie the alterations in human gamma delta T cells remain largely unclear. In this study, we have investigated the molecular characteristics of human gamma delta T cells related to their acquisition of antigen-presenting capacity in comparison with activated alpha beta T cells. We found that activated gamma delta but not alpha beta T cells upregulated cell surface expression of a scavenger receptor, CD36, which seemed to be mediated by signaling through mitogen-activated protein kinase and/or NF- Kappa B pathways. Confocal microscopical analysis revealed that activated gamma delta T cells can phagocytose protein antigens. Activated gamma delta T cells could induce tumor antigen-specific CD8 super(+) T cells using both apoptotic and live tumor cells as antigen resources. Furthermore, we detected that C/EBP alpha , a critical transcription factor for the development of myeloid-lineage cells, is expressed much higher in gamma delta T cells than in alpha beta T cells. These results unveiled the molecular mechanisms for the elicitation of antigen-presenting functions in gamma delta T cells and would also help designing new approaches for gamma delta T cell-mediated human cancer immunotherapy. |
---|---|
ISSN: | 0340-7004 1432-0851 |
DOI: | 10.1007/s00262-015-1700-x |